RLMD Fail-to-Deliver
Relmada Therapeutics, Inc. (RLMD) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $352.4M, listed on NASDAQ, employing roughly 17 people, carrying a beta of 0.45 to the broader market. Relmada Therapeutics, Inc. Led by Sergio Traversa, public since 2014-06-20.
No records carrying symbol RLMD appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 28, 2026 through September 14, 2026.
Most recent fail-to-deliver in our records: August 27, 2026.
Frequently asked RLMD fail-to-deliver questions
- Has RLMD had any fails-to-deliver recently?
- No records carrying symbol RLMD appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 28, 2026 through September 14, 2026. Most recent fail-to-deliver in our records: August 27, 2026. The SEC publishes the first half of each month at the month's end and the second half around the 15th of the next month, so this check covers settlement dates through September 14, 2026.
- What does it mean when RLMD is absent from the SEC fails-to-deliver data?
- The SEC's files give the aggregate net balance of shares that failed to be delivered in NSCC's Continuous Net Settlement system, by security and settlement date. Since September 16, 2008 a security has a record for every settlement date on which that balance was above zero, and none when it was zero. This check is by symbol, so a fail reported only under a CUSIP or a former symbol is not counted.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
Learn how fails-to-deliver is reported and how to read the data →